Coastal Bridge Advisors LLC lessened its holdings in Pfizer Inc. (NYSE:PFE) by 1.1% in the second quarter, HoldingsChannel.com reports. The firm owned 30,595 shares of the biopharmaceutical company’s stock after selling 349 shares during the period. Coastal Bridge Advisors LLC’s holdings in Pfizer were worth $1,198,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors have also added to or reduced their stakes in PFE. TD Capital Management LLC lifted its holdings in Pfizer by 12.0% in the 2nd quarter. TD Capital Management LLC now owns 2,183 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 234 shares during the last quarter. Highland Private Wealth Management lifted its holdings in shares of Pfizer by 2.8% during the second quarter. Highland Private Wealth Management now owns 8,698 shares of the biopharmaceutical company’s stock worth $341,000 after buying an additional 238 shares during the last quarter. HawsGoodwin Investment Management LLC lifted its holdings in shares of Pfizer by 0.8% during the second quarter. HawsGoodwin Investment Management LLC now owns 30,141 shares of the biopharmaceutical company’s stock worth $1,180,000 after buying an additional 239 shares during the last quarter. TAP Consulting LLC lifted its holdings in shares of Pfizer by 1.2% during the second quarter. TAP Consulting LLC now owns 20,633 shares of the biopharmaceutical company’s stock worth $808,000 after buying an additional 246 shares during the last quarter. Finally, Mirador Capital Partners LP lifted its holdings in shares of Pfizer by 1.1% during the second quarter. Mirador Capital Partners LP now owns 22,092 shares of the biopharmaceutical company’s stock worth $865,000 after buying an additional 247 shares during the last quarter. 64.93% of the stock is owned by hedge funds and other institutional investors.
In other Pfizer news, SVP Jennifer B. Damico sold 1,661 shares of the stock in a transaction dated Friday, August 13th. The stock was sold at an average price of $48.30, for a total value of $80,226.30. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Jennifer B. Damico sold 2,500 shares of the stock in a transaction dated Friday, July 30th. The shares were sold at an average price of $42.86, for a total value of $107,150.00. Following the completion of the transaction, the senior vice president now directly owns 11,430 shares in the company, valued at approximately $489,889.80. The disclosure for this sale can be found here. 0.05% of the stock is currently owned by corporate insiders.
Pfizer (NYSE:PFE) last announced its earnings results on Wednesday, July 28th. The biopharmaceutical company reported $1.07 EPS for the quarter, topping the consensus estimate of $0.97 by $0.10. The company had revenue of $18.98 billion for the quarter, compared to analysts’ expectations of $17.54 billion. Pfizer had a return on equity of 26.49% and a net margin of 23.06%. During the same quarter in the prior year, the business earned $0.78 earnings per share. As a group, sell-side analysts expect that Pfizer Inc. will post 4.12 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 7th. Stockholders of record on Friday, July 30th were issued a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 3.48%. The ex-dividend date was Thursday, July 29th. Pfizer’s payout ratio is presently 70.27%.
PFE has been the subject of a number of research analyst reports. Berenberg Bank reiterated a “neutral” rating and set a $43.00 price target on shares of Pfizer in a report on Tuesday, June 15th. Morgan Stanley upped their price target on Pfizer from $42.00 to $45.00 and gave the stock an “equal weight” rating in a report on Thursday, July 29th. Truist began coverage on Pfizer in a research note on Tuesday, July 27th. They issued a “buy” rating and a $43.00 target price for the company. The Goldman Sachs Group set a $48.00 target price on Pfizer in a research note on Thursday, July 29th. Finally, JPMorgan Chase & Co. upped their target price on Pfizer from $40.00 to $42.00 and gave the company a “neutral” rating in a research note on Monday. Eleven research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $42.77.
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
Recommended Story: What is Forex?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.